AN UPDATE ON TOXICITY OF THERAPEUTIC RADIONUCLIDES

Authors
Dilip Harindran Vallathol MBBS, MD, DM
Raghunadharao Digumarti MBBS, MD, DM, FRCP (Lond), FACP

Affiliation
Department of Medical Oncology, Homi Bhabha Cancer Hospital & Research Centre, Visakhapatnam, Andhra Pradesh, India.

Correspondence
Raghunadharao Digumarti
Email: rdigumarti@gmail.com

ABSTRACT
Targeted radiotherapy is an evolving and promising modality of cancer treatment. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. A number of radionuclides, such as iodine-131 ($^{131}$I), phosphorus-32 ($^{32}$P), strontium-90 ($^{90}$Sr), and yttrium-90 ($^{90}$Y), have been used successfully for the treatment of many benign and malignant disorders. The toxicity to radionuclides has come into vogue with its increasing utilization for multiple indications. Short term hematological toxicities include cytopenias and long term hematological toxicities include myeloid neoplasms. Non hematological toxicities commonly include renal and hepatotoxicity and long term toxicities like gonadal toxicity. This review focuses on the toxicities which need to be monitored during use of therapeutic radionuclides.
INTRODUCTION
Theranostics is a revolutionary approach that promises improved therapy selection on the basis of specific molecular features of disease, greater predictive power for adverse effects due to improved patient specific absorbed dose estimates, and new ways to objectively monitor therapy response. The history of radionuclide therapy can be traced back to the early 1900s, after the discovery of radioactivity by Henri Becquerel and Marie Curie. Radionuclide based targeted therapies have emerged as an effective mode of cancer treatment in the recent decades. Specific physical characteristics of Targeted Radionuclide Therapies (TRT) (heterogeneous and mixed irradiation, protracted exposure and low absorbed dose rate) differ from those of conventional EBRT (homogeneous irradiation, short exposure, and high absorbed dose rate), and, consequently the response of irradiated tissues might be different\(^1\).

An ideal radiopharmaceutical for therapeutic purposes should:
- Act exclusively on cancer cells
- Reach all the cancer cells wherever they are localized
- Leave healthy tissues and organs unhurt while bringing maximum doses of radiation to the tumour
- Eliminate malignant tumour cells with great effectiveness

Many therapeutic radionuclides are in use for multiple indications. Hence the question of toxicity, both short term and long term, has come into picture. In this article we try to focus on toxicities of radionuclides in terms of its classification, the risk of toxicity and how to mitigate them.

RADIONUCLIDES IN ONCOLOGY
There have been vast advances in the field of TRT in oncology. They are being used in various modes and forms for both therapeutic and diagnostic purposes. Table 1 gives a short list of various radionuclide agents used in the field of oncology.

Table 1 Commonly used radionuclide in oncology (therapeutic and diagnostic)\(^2\)

<table>
<thead>
<tr>
<th>Name</th>
<th>Properties</th>
<th>Oncologic Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radium (^{223})</td>
<td>Produced by decay of thorium (^{227})---&gt;Calcium analogue, accumulates in sites of bone mineralisation</td>
<td>Bone metastasis especially from prostate cancer</td>
</tr>
<tr>
<td>Actinium (^{225})</td>
<td>Degrades to Bi (^{213}), accumulates primarily in the liver and bone</td>
<td>AML, ovarian cancer, breast cancer, neuroblastoma, glioblastomas, prostate cancer</td>
</tr>
<tr>
<td>Beta emitters</td>
<td>Radioimmunoconjugate</td>
<td>Radioembolization of liver microvasculature</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>----------------------</td>
<td>-------------------------------------------</td>
</tr>
<tr>
<td>Yttrium$^{90}$ (resin and glass microspheres)/Rhenium$^{188}$</td>
<td>Radioimmunoconjugate</td>
<td>Radioimmunotherapy with Yttrium$^{90}$ ibritumomab tiuxetan</td>
</tr>
<tr>
<td>$^{131}$I radioiodine</td>
<td>Radioimmunoconjugate</td>
<td>Active uptake through Na–I symporter and storage in follicular cells</td>
</tr>
<tr>
<td>$^{153}$Samarium</td>
<td>Radioimmunoconjugate</td>
<td>Tositumomab</td>
</tr>
<tr>
<td>$^{177}$Lu-labelled DOTATATE</td>
<td></td>
<td>Somatostatin Receptor-mediated binding</td>
</tr>
<tr>
<td>$^{131}$lmIBG</td>
<td></td>
<td>Active uptake mechanism via the adrenaline transporter and storage in presynaptic neurosecretory granules</td>
</tr>
</tbody>
</table>

**Auger electron therapy**

| Technetium$^{99m}$                               |                      | Rich coordination chemistry with several potential oxidation states | For diagnostic imaging—Bone scan, Glomerular filtration rate estimation, liver, thyroid and parathyroid imaging, estimation of response to chemotherapy |
| Gallium$^{67}$                                    |                      | Photon emitting radiotracer for scintigraphy                          | Evaluation of tumors including lung, liver, brain etc, inflammatory conditions |
| Indium$^{111}$                                    |                      | Decays by electron capture to cadmium Cd$^{111}$                         | Imaging of various tumors                                             |
Therapeutic radionuclides are divided into energetic particles which include alpha emitters and beta emitters and non energetic particles. The selection of the appropriate radionuclide depends on its decay properties, specifically, emission characteristics and physical half-life. The radionuclides most commonly used in therapy emit particles with a low penetration range and high linear energy transfer (LET), leading to high ionization in the uptake site. A suitable range of the physical half-life for therapeutic radionuclides is between 6 hours and 7 days. A very short physical half-life limits the delivery flexibility and is very impractical, while a long half-life allows for the retention of the radiation dose in the patient and exposes surrounding people for a longer period.

The treatment of bulky tumors by radionuclides that emit high energy alpha or beta particles is the preferred approach; however, for the eradication of small clusters of cancer cells or small tumor deposits, radionuclides that emit Auger electrons are considered to be beneficial because of their high level of cytotoxicity and short-range biological effectiveness.

Structure of Targeted Radionuclide Therapy

The theranostic principle in nuclear medicine involves combining diagnostic imaging and therapy with the same molecule, which is radio-labeled differently, or administered in other dosages. The image shows a simplified model of a radiopharmaceutical, which consists of a binding molecule that binds the target, and a linking molecule, which binds the radioisotope. Examples of such theranostic molecules are DOTA-TOC, DOTA-TATE, and $^{617}\text{PSMA}$.

**MECHANISM OF ACTION**

The distribution of therapeutic radiopharmaceuticals within a targeted solid...
tumor is not homogeneous⁷. This is mainly a result of:

(i) The radio-labeled molecules to penetrate non-uniformly within a solid tumor mass

(ii) The high interstitial pressure of solid tumors; and/or

(iii) Differences in the binding-site densities of tumor cells.

**Energetic particles**

These include alpha emitters and beta emitters.

The probability of the energetic particles traversing the targeted cell nucleus depends on:

(i) The position of the decaying atom vis-à-vis the nucleus – specifically nuclear DNA – of the targeted tumor cell

(ii) Distance from the tumor cell nucleus

(iii) Radius of the latter

**Table 2  Differences between alpha and beta particles⁷**

<table>
<thead>
<tr>
<th>Properties</th>
<th>Alpha Particle</th>
<th>Beta Particle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Particle type</td>
<td>Helium⁴ nucleus</td>
<td>Energetic electron</td>
</tr>
<tr>
<td>Particle energy</td>
<td>5-9 Mev</td>
<td>50-2300 keV</td>
</tr>
<tr>
<td>Particle path length</td>
<td>40 to 100 microns</td>
<td>0.05 to 12 mm</td>
</tr>
<tr>
<td>Linear energy transfer</td>
<td>Approx 80keV/micron metre</td>
<td>0.2 keV/Micronmetre</td>
</tr>
<tr>
<td>Oxygenation</td>
<td>Effective in hypoxic tumors</td>
<td>Less effective in hypoxic tumors</td>
</tr>
<tr>
<td>Dose rates</td>
<td>Exponential reduction in tumor survival with increase in absorbed dose</td>
<td>Tumor survival close to linear exponential dose rates</td>
</tr>
<tr>
<td>Bystander effect</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Tumor cross fire</td>
<td>Low</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Non Energetic particles**

During the decay of certain radioactive atoms, a vacancy is formed as a consequence of electron capture (EC). The transition results in the emission of characteristic Auger electrons. In an atom undergoing EC, on average, 5–30 Auger electrons with energies ranging from a few eV to approximately 1 keV are emitted. These are light, negatively charged particles that travel in contorted paths and their range in water is up to ~0.5 µm and result in multiple ionizations at the decay site. Thus, the short range of Auger
electrons necessitates the close proximity to
the target (tumour) for its radio-therapeutic
effectiveness.$^8$

**MECHANISM OF TOXICITY TO
RADIONUCLIDE THERAPY**

A definition of toxicity *hazard* for a
radionuclide is the probability that injury
may be caused by the manner in which the
radionuclide is used.$^9$. The toxicity to
radionuclide is mostly related to the
associated relative biological efficiency
(RBE) dose, which is defined as the ratio of
the doses required by two different radiations
to cause the same level of effect.$^10$. The RBE
of a given type of radiation will vary with
particle type and energy, dose, dose per
fraction, degree of oxygenation, cell or tissue
type, biological endpoint, etc.

The types of radiation emitted, and their
energies, have been well-established for most
radionuclides and the disintegration rate of
any radioactive sample can be measured.
Therefore, if the concentration of a
radionuclide by a body organ of known mass
can be determined from experimental
measurement, then the dose in rads delivered
to the organ by the radionuclide can be
calculated.$^11$. The product of RBE x dose (rad)
is proportional to the risk of biological
damage for all types of radiation.$^9$.

**Time frame of toxicity**

The toxicity to radionuclides can be
classified into either acute or chronic.
Response and toxicity prediction is essential
for the rational implementation of cancer
treatment using radionuclide therapy. As
mentioned earlier, the biological effects of
radionuclide therapy are mediated by a well-
defined physical quantity, the absorbed dose,
which is defined as the energy absorbed per
unit mass of tissue.$^2$.

**Standardised capture and reporting of
toxicity**

Existing methods like the NCI's Common
Terminology Criteria for Adverse Events
(CTCAE, version 5) are reliable and accurate
for describing toxicities on a five-point scale
based on clinical criteria. The NCI recognizes
five discrete categories for any given CTCAE
term that radiopharmaceutical-attributed
toxicity must fit.$^{12}$:

(A) laboratory/biomarker based toxicity that
requires equipment to detect (like anemia,
leukopenia, neutropenia, or thrombocytopenia)

(B) observable/measurable toxicity that
requires technical training to delineate (like
eye examination for tearing caused by
corneal or limbic irritation)

(C) primarily subjective toxicity without
observable components (like radiation-
induced nausea)

(D) primarily subjective toxicity with
observable components (like radiation-
induced diarrhea)

(E) primarily observable toxicity with
subjective components (like radiation-
induced alopecia)
Table 3: Time frame to toxicity$^{13,14}$

<table>
<thead>
<tr>
<th>Effects</th>
<th>Time relative to exposure</th>
<th>Time duration</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute toxicity</td>
<td>Arises over a brief timeframe</td>
<td>Transient, reversible or persistent</td>
<td>Nausea</td>
</tr>
<tr>
<td>Subacute toxicity</td>
<td>Arises over intermediate time period (1-3 months post therapy)</td>
<td>Transient, reversible or persistent</td>
<td>Pneumonitis</td>
</tr>
<tr>
<td>Chronic toxicity</td>
<td>Arises over a long time frame</td>
<td>Persistent, intermittent</td>
<td>Fibrosis</td>
</tr>
<tr>
<td>Cumulative toxicity</td>
<td>Arises and intensifies after repeated exposure</td>
<td>Persistent, intermittent</td>
<td>Watering eyes</td>
</tr>
<tr>
<td>Late toxicity</td>
<td>Arises over a long time frame after repeated exposure</td>
<td>Persistent, intermittent</td>
<td>Marrow hypoplasia</td>
</tr>
</tbody>
</table>

**Risk factors for toxicity**

The risk factors for radionuclide toxicity may be multifactorial but are unclear.

A patient who has received any form of cancer therapy (chemotherapy or radiotherapy) is deemed to have more toxicity due to poor bone marrow reserve; hence, toxicity may be attributed to pre-exposure to these agents.

For the kidney, these factors might include long-standing and poorly controlled hypertension or diabetes$^{15}$.

Similarly, advanced age is also a risk factor for toxicity due altered organ functions. The role of clinical factors for predicting toxicity in NETs (neuroendocrine tumours) is unclear.

Identifying intrinsic susceptibility to radiation exposure is a key need that is unmet in the field of radiation oncobiology, to reduce severe, unpredictable effects in the long-term.

Seven Single Nucleotide Polymorphisms (SNPs) have been associated with late effects of radiotherapy. Genes range from TGFβ1 (growth factor signaling) to SLC36A4 (high affinity amino acid transporter) and are associated with endpoints related to toxicity, including fibrosis and overall toxicity$^{16}$.

Gene expression profiling has also been used to study these toxic effects. Although these genes have been defined for external radiotherapy, they represent potential candidate factors for toxicity related to PRRT (peptide receptor radionuclide therapy$^{17}$).

Proper monitoring of liver function and renal function tests are paramount during delivery of radionuclides.

**Toxicities of commonly used radionuclides**
Most of the toxicities with radionuclide are related to those associated with radiotherapy. Most studied among them are related to Peptide Receptor Radionuclide Therapy (PRRT). Hematologic and renal toxicities are dose limiting for radionuclide therapy.

**Acute and subacute toxicity**

Most common acute toxicities include

**Nausea and Vomiting** - Anticipatory, acute and delayed vomiting have been described with radionuclide therapy as with radiation. The pathophysiology of radiation-induced emesis is complex. It has been suggested that both serotonin levels and the abdomen play important roles in radiation-induced nausea and vomiting.  

**Fatigue** - Fatigue is associated with all forms of cancer therapy. The mechanism is complex. The recent evidence suggests it is related to mitochondrial dysfunction. The individual’s inflammatory response is another mechanism that is proposed to contribute to fatigue.

**Xerostomia** - Radiation induced xerostomia and hyposalivation are multifactorial. The primary cause of irreversible hyposalivation is loss or impairment of acinar cells and their progressive replacement by connective tissue and fibrosis. The frequency and extent of the resulting symptoms are dependent on the absorbed dose and the isotope used.

**Hematological toxicity**

Acute hematological toxicities include cytopenias. Acute toxicity manifested as modest self-limited grade 3/4 toxicity (CTCAE or WHO), most often affecting platelets, white blood cells (WBC), and, finally hemoglobin. Lymphopenia is also characteristic but the exact mechanism is not known. This is commonly observed during the first cycle of treatment, with the lowest nadir predictive of time taken for recovery during the first cycle of treatment. Toxicity manifesting early is easily managed with dose modification or therapy cessation and was ameliorated by appropriate patient selection.

**Renal toxicity**

The kidneys have been considered as the “critical organ” because of the predominant glomerular filtration, tubular reabsorption and retention of the tracer by the proximal tubules. Severe nephrotoxicity depends on several factors, such as the amount of the single and cumulative administered radiopharmaceutical activity, treatment interval between the cycles, radioisotope which was preferred, renal absorbed dose, presence of patients’ risk factors, and features of renal protection. Studies on the mechanism and localization demonstrate that renal uptake of radio-labeled somatostatin analogues largely depends on the megalin/cubulin system in the proximal tubule cells. Thus, methods are needed that interfere with this reabsorption pathway to achieve kidney protection.

**Hepatotoxicity**

Hepatotoxicity has not been completely studied with radionuclide therapy. There have been case series and reports of hepatotoxicity occurring in metastatic neuroendocrine tumors post PRRT.

Radiation-induced hepatitis is a subacute toxicity and is thought to likely to occur when
previous dose radiation has been delivered as a cumulative effect\textsuperscript{24}.

There have also been case series studies of hepatotoxicity following transarterial radio-embolization with Yttrium 90 microspheres and usually occurs as subacute to late toxicity, but assessment is challenging as it is usually used in a palliative setting\textsuperscript{25,26}.

**Chronic toxicity**

**Hematological toxicity**

Cumulative toxicity from radionuclides can result in bone marrow failure syndromes and malignancies\textsuperscript{27}. Risk factors such as use of alkylating agents, metastatic disease to the bone, prior radiation, and others are associated with development of therapy related myeloid neoplasms\textsuperscript{28,29} (t-MN). There have also been studies suggesting that early occurrence of cytopenias is related to development of hematological malignancies. However, these factors have not been consistently implicated across studies. Recent reports suggest an association between preexisting somatic mutations and subsequent development of t-MN\textsuperscript{30}.

**Renal toxicity**

Acute nephropathy can spontaneously recover or progress to chronic radiation nephropathy, which is characterized by volume loss and functional decline\textsuperscript{31}. The latent period before the onset of the radiation-induced functional impairment depends on the cell turnover rate of the tissue. Kidney parenchyma is a slow turnover tissue, thus there is latency period before the functional damage is clinically detectable. Therefore, it is important to follow-up the renal function over a long period of time\textsuperscript{23}.

**Gonadal dysfunction**

The major sources of irradiation to the gonads are from circulating radioactive particles and its accumulation in the bladder and rectum. Reduction in sperm count and damage to germinal epithelium are known to occur with radionuclide therapy which can lead to infertility in rare cases\textsuperscript{32}.

**Side effects of specific commonly used radionuclides**

**Peptide receptor radionuclide therapy**

In a review of 2225 patients treated with PRRT, short-term myelotoxicity was observed in 221 patients (10%), occurring in 213 of 2104 patients treated with PRRT monotherapy and 8 of 121 patients treated with PRRT combined with chemotherapy\textsuperscript{21}.

In another study by Bergesma \textit{et al}, The prevalence of therapy-related persistent hematological dysfunction after PRRT with $^{177}$Lu-DOTATATE in GEP-NET patients was 3.7% implying a RR of 2.7. The median latency time to disease development was 41 months\textsuperscript{33}.

In the phase 3 netter trial with lutetium 177 therapy in gut neuroendocrine tumors, the most common adverse events were nausea and vomiting and then fatigue and asthenia. Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia were reported in 1%, 2%, and 9% of patients\textsuperscript{34}.

In a recent systematic review by Sonbol \textit{et al} which included 28 articles and 7334 patients, it was reported that cumulative incidence of
t-MN after PRRT is 2.61% (4.38%). This incidence appears to be higher than is reported in other malignant neoplasms like breast and gastrointestinal cancers. The median time for development of therapy related myeloid neoplasms 33.8 months to. Thus, the latency period more closely resembles the 1 to 3 year period seen after treatment with topoisomerase-2 inhibitors27.

There have been several studies which have looked at salivary toxicity due to radionuclides, especially with lutetium 177 therapy and PSMA therapy. Xerostomia higher than grade 1 occurred more frequently in patients receiving a higher number of fractions. Most patients reported recovery from xerostomia after a few weeks. The duration of the symptoms was longer after the second or third therapy in most cases35,36.

In one large institutional series of 1109 NET patients treated with 90YDOTATOC, 103 patients (9%) experienced severe permanent renal toxicity, and the initial kidney uptake was found to be predictive for kidney damage in multivariable analysis37.

A retrospective analysis of 807 patients treated with PRRT showed severe (grade 3/4) permanent nephrotoxicity was observed only in 1.5% of patients, and pre-existing nephrototoxic risk factors were shown to have a limited role in predicting PRRT-induced renal insufficiency28. Overall, end-stage renal failure following PRRT is extremely rare.

**Radioiodine ablation therapy**

Nausea, lacrimal gland dysfunction and altered taste have been known to occur with radioiodine therapy with increasing doses. Radiation-induced depressed bone marrow function is manifested as a transient reduction in platelet and leukocyte counts may occur 3 to 5 weeks after 131I administration. It is a dose-dependent response that usually recovers within 6 months38. Persistent marrow depression, however, may be seen in patients with renal insufficiency39. Patients with multiple bone metastatic lesions treated with large cumulative administrations of 131I experience more severe marrow toxicity, which may lead to myelodysplasia or aplastic anemia40. Leukemia has been reported, primarily in patients with multiple bone metastatic tumors who receive >18.5 GBq (500 mCi) of radioiodine32,41.

The long-term toxicities of RAI include secondary primary malignancy 42,43 (SPM), sialadenitis, nasolacrimal duct obstruction and infertility39.

Permanent salivary gland damage after 131I manifesting as xerostomia or salivary gland swelling has also been reported. It may be associated with transient symptoms at the time of therapy, or which appear months or even years later44. Symptoms of dry mouth or swelling persisted for up to 2.5 years in 10% of one series. In another study, 43% had persistent salivary gland complaints 12 months after 131I administration45. A small increase in the incidence of salivary gland neoplasms years after 131I therapy has been reported.46,47

Gonadal dysfunction also has been reported in both males and females after radioiodine therapy. Transient amenorrhea and menstrual irregularities occurred in 25% of women receiving 131I therapy for thyroid
cancer in a previously published series. Onset was a few months after administration of $^{131}$I, and symptoms lasted from 4 to 10 months. However, permanent infertility has not been reported. Similarly in males, temporary damage to the germinal epithelium is reflected by a transient elevation of levels of follicle-stimulating hormone, with normalization by 9 to 12 months after the last $^{131}$I administration. 

The cumulative dose of $^{131}$I correlated with the risk of bone, soft tissue, colorectal, and salivary gland cancers. In a meta-analysis that included 2 multicenter studies, the relative risk of leukemia in thyroid cancer survivors treated with $^{131}$I was 2.5 (95% confidence interval, 1.13 to 5.53; P = .024). In a more recent meta-analysis, the risk ratio of any Secondary Neoplasms in RAI-treated TC patients was 0.98 ([confidence interval (CI) 0.76-1.27]. The pooled risk ratio for any neoplasm, adjusted for confounders, was 1.16 In secondary analyses examining specific neoplasm., although relatively rare, the risk of subsequent leukemia was increased.

Radium $^{223}$ therapy

In the phase 3 alsympca trial of metastatic prostate cancer treated with radium 223, common toxicities noted were nausea, bone pain, and anemia. Grade 3 or 4 hematological side effects observed were anemia (13%) , neutropenia (2%), and thrombocytopenia(6%). McKay et al evaluated 135 patients with mCRPC, 7 patients discontinued Ra-223 early for toxicity, and the independent predictors of therapy completion in a multivariable analysis included previous treatment with sipuleucel-T, hemoglobin, and ANC greater than the lower limit of normal.

In a post hoc analysis of alsympca trial, baseline characteristics of patients in the Ra-223 safety arm significantly associated with the development of grade 2 to 4 anemia were the extent of disease, higher PSA levels, higher total ALP levels, and lower baseline hemoglobin levels.

Recently, the US FDA conducted an adverse event reporting analysis and found 2182 radium$^{223}$ cases associated with AE(s) from 2013 to 2018, as part of post marketing surveillance. The results of disproportionality analysis, conducted in a heterogenous group of patients, revealed strong signals for multiple hematologic AEs (anemia, thrombocytopenia, pancytopenia/bone marrow failure, and leukopenia). The gastrointestinal toxicities which include diarrhea and nausea were also commonly reported.

There have been very rare case reports of secondary malignancies post radium 223 therapy, but longer follow up is required for a more specific recommendation in this regard.

MIBG therapy

In a retrospective analysis of 66 neuroblastoma patients treated with MIBG therapy, the main grade 4 toxicity observed was haematological, occurring in stage 4 patients, after the first and second $^{131}$I-MIBG therapies. Nausea, vomiting and fever were
common toxicities which occurred post infusion\textsuperscript{55}.

Infections have also been reported during and after \textsuperscript{131}I-MIBG therapy in heavily pretreated patients and in patients treated with myeloablative \textsuperscript{131}I-MIBG therapy. Matthay et al. found infectious events (grade 3 or 4) in 10.9\% of patients with refractory neuroblastoma\textsuperscript{56}.

In another study of 22 patients of neuroendocrine tumors (NET) treated with MIBG, toxicity was confined to transient myelosuppression of grade 3 or 4 in 15.3\% (leukopenia) and 7.6\% (thrombocytopenia) and a late event of myelodysplastic syndrome, after a cumulative administered activity of 66.6 GBq. The most frequent non hematologic side effect was mild nausea (grade 1 or 2), which was observed in 28\% of administered cycles\textsuperscript{57}.

In another recent study 68 patients of advanced paraganglioma and pheochromocytoma treated with high specific activity MIBG, most common treatment-emergent adverse events were nausea, myelosuppression, and fatigue. Sixty-one patients (90\%) experienced hematologic AEs, which were grade 3 or 4 AEs or SAEs in 49 (72\%) of these patients\textsuperscript{58}.

Drug induced hypertension and thyroid dysfunction has also been reported with MIBG therapy. Cases of late onset leukemia and myelodysplastic syndromes have also been reported post MIBG therapy\textsuperscript{59}.

**Yttrium 90 therapy**

An increased incidence of cirrhosis or fibrosis following \textsuperscript{90}Y for NET has been reported in several analyses\textsuperscript{60}. The rate doubled in those treated with whole-liver infusion. Radiation-induced hepatic fibrosis has also been noted\textsuperscript{61}. There have been few reports of fatal toxicities in patients with metastatic NET following radioembolization. Whitney. report an episode of hepatic failure one month following radioembolization\textsuperscript{62}. Su et al. report et al death from hepatic failure in 2 of patients in the absence of disease progression or subsequent therapies, while 6 additional patients died of liver failure in the setting of disease progression and subsequent exposure to potentially hepatotoxic systemic therapies\textsuperscript{63}.

The most common AEs with \textsuperscript{90}Y-ibritumomab tiuxetan are hematologic toxicities as per various prospective and retrospective studies\textsuperscript{64}. Dosimetric analysis demonstrated that radiation exposure with \textsuperscript{90}Y-ibritumomab tiuxetan consolidation was within safe limits both to normal organs and to red marrow. Incidence of second malignancies has also been reported around 2.5\%. Fatigue and thyroid dysfunction have also been reported\textsuperscript{65}.

**Mitigating side effects**

The mainstay of avoiding excess side effects is to calculate the exact dose using standardised dosimetry calculators.

For radioimmunotherapy, the normal organ dose limitations depend mainly on the dose absorbed by the bone marrow. One way to avoid unnecessary bone marrow exposure is to ensure a rapid clearance from blood, for instance by administering small molecules,
such as bivalent or monovalent antibody fragments instead of intact IgG\textsuperscript{66}.

Preventive strategies have not been successful in mitigating the side effects of salivary gland function (local cooling, lemon juice and vitamin C, or a displacement strategy using PMPA \textsuperscript{20} (phosphonomethyl)pentane-1,5-dioic acid)). Salivary gland toxicity is reported to be low when low-dose \textsuperscript{131}I ablation is used. In one study\textsuperscript{47}, pain and tenderness over the salivary glands occurred in only 1.78% of patients receiving low-dose (1.48 GBq) \textsuperscript{131}I. Maximal reactions were experienced 24–48 h after therapy and all symptoms except xerostomia resolved within 1 week. Amifostine, which acts as a scavenger of oxygen-free radicals that mediate radiation-induced tissue damage, may help to reduce salivary gland damage\textsuperscript{67}.

Co-infusion of competitive inhibitors of re-absorption also interferes with the interaction of peptides with renal endocytic receptors; co-infusion of basic amino acids is currently used for kidney protection in clinical PRRT. Patient specific dosimetry may be helpful in minimizing the renal absorbed dose while maximizing the tumor dose. In addition, close and accurate renal function monitoring using more precise methods, rather than plasma creatinine levels, is essential to diagnose the early renal functional changes and to follow-up the renal function during the treatment\textsuperscript{22}.

Avoidance of gonadal toxicity can be achieved by preventing accumulation of radioactivity in the bladder or rectum. Advice regarding excess fluid intake and emptying the bladder frequently should be explained. Constipation should be avoided and laxatives may be used\textsuperscript{32}. Male patients likely to require repeated doses of radioiodine (cumulative dose >14 GBq) should be offered sperm banking because of the potential for low sperm counts\textsuperscript{68}.

CONCLUSION

Radionuclide therapy has opened new avenues for treatment and diagnostics in malignancies. In general, the toxicity risk seems to depend on the characteristics of the molecule, such as the molecular weight, electric charges and clearance pathways and the chemical and physical characteristics. Many new radionuclides for various indications are on the horizon; hence, their use is likely to escalate. They are generally considered safe. Many of the toxicities are similar to those associated with traditional radiation therapy. One should be aware of the long term toxic effects of these radionuclides which will come into picture on further long term follow ups.
BIBLIOGRAPHY


9) International Atomic Energy Agency, A Basic Toxicity Classification of Radionuclides, Technical Reports Series No. 15, IAEA, Vienna


17) Bodei L, Schöder H, Baum RP, et al. Molecular profiling of neuroendocrine


32) Hyer SL, Newbold K, Harmer CL. Early and late toxicity of radioiodine therapy:


42) Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. *J Clin Endocrinol Metab.* 2008;93(2):504-515. doi:10.1210/jc.2007-1154


60) Zuckerman DA, Kennard RF, Roy A, Parikh PJ, Weiner AA. Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases


